With 8.7 % CAGR, Sepsis Diagnostics Market Worth will be USD 1509.85 Million by 2030

The global sepsis diagnostics market is expected to reach USD 1509.85 million in 2030 from USD 712.74 million in 2021, and estimated to grow at a CAGR of 8.7% during the forecast period from 2021-2030. Growing Incidence of hospital-acquired infections along with the rising demand for rapid diagnostic tests to fuel the industry growth, states Strategic Market Research.

New York, USA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- The Worldwide Sepsis Diagnostics Market value in 2021 was USD 712.74 million, and by 2030 it will reach USD 1509.85 million with a 8.7% CAGR. Sepsis is a severe condition that arises when the body reacts to an infection that causes tissue damage. Bacterial infections are the prominent cause of sepsis, while viral infections can also lead to sepsis. A post-surgery infection or a small wound that becomes infected might trigger sepsis. Sepsis can result in multiple organ failures, septic shock, and death if it is not diagnosed and treated properly.

To get a first-hand overview of the report, Request a Sample at

Sepsis Diagnostics Market Insights: 

  • In terms of product, in 2021, the blood culture media segment held a dominant position with a market share of over 45.5%.
  • The microbiology segment recorded a maximum revenue share of more than 48.5% on the basis of technology.
  • The bacterial sepsis segment in 2021 held a dominant position with a revenue share of nearly 79.5% in terms of pathogens.
  • On the basis of testing type, in 2021, the laboratory testing type segment held the highest revenue share of over 85%.
  • North America ruled the overall market by region, with a revenue share of nearly 39.7% in 2021.

Factors influencing the Sepsis Diagnostics Market growth

Factors like the increasing incidence of infectious disease and hospital-acquired infection are influencing its growth rate. 

  • Factors such as the increasing cases of infectious diseases such as cholera, pneumonia, salmonellosis, toxic shock syndrome, COVID-19, and other diseases are stimulating the overall growth of the sepsis diagnostics market. As per data issued by the World Health Organization in February 2021, approximately 1.3-4.0 million cases of cholera are recorded each year globally. In addition, a study by the National Center for Biotechnology Information (NCBI) in November 2020 found that the prevalence of toxic shock syndrome in the United States ranged from 0.8 to 3.4 per 100,000 people.
  • Every hospitalized patient is at risk of developing hospital-acquired infections (HAI). Long hospital stays, healthcare staff who don't wash their hands, and increased dependence on antibiotics are additional risk factors. Urinary Tract infections (UTIs) and Surgical-Site Infections (SSIs) are the most common hospital-acquired infections, which can lead to sepsis. The Centers for Disease Control and Prevention stated that hospital-acquired infections (HAIs) are responsible for approximately 100,000 fatalities annually and 1.7 million infections, with urinary tract infections contributing to 32%, pneumonia for 15%, surgical site infections for 22%, and blood infections for 14%.

Sepsis Diagnostics Market: A thorough Segmentation Analysis

The worldwide sepsis diagnostics Market segmentation has been done on the basis of product, technology, pathogens, testing type, and region. 

By Product:

  • Software Products
  • Instruments
  • Blood Culture Media
  • Assays and Reagents

By Technology

  • Microbiology
  • Immunoassay
  • Molecular Diagnostics

By Pathogens

  • Bacterial Sepsis
  • Fungal Sepsis
  • Other Pathogens

By Testing Type

  • Laboratory Testing
  • POC Testing

By Region

  • South America
  • Europe
  • Asia-Pacific
  • North America
  • Middle-East and Africa

Make a Direct Purchase of the latest Sepsis Diagnostics Market Report published in the month of Sep-2022. Click the below link to initiate the purchase: 


In terms of product, in 2021, the blood culture media segment held a dominant position with a market share of over 45.5%. This is because clinicians consider blood cultures as the most efficient and affordable testing method. A blood culture is a clinical test that identifies bacteria or fungi in the blood of a person. Microorganisms do not normally exist in blood, but their presence can indicate a bloodstream infection such as fungemia or bacteremia, which can result in sepsis.

The microbiology segment recorded a maximum revenue share of more than 48.5% on the basis of technology. Microbiology technology enables accurate detection and identification of bacteria for sepsis diagnosis via culture medium assays. Furthermore, new strategic initiatives by key players are also stimulating the segment's expansion. 
Over the projected period, the molecular diagnostics segment is expected to grow at the highest CAGR. The segment is expected to be driven by the implementation of molecular diagnostic technology because of its many benefits, including accuracy, high sensitivity, and fast response time compared to other technologies.

The bacterial sepsis segment in 2021 held a dominant position with a revenue share of nearly 79.5% in terms of pathogens. Factors such as an increase in hospital-transmitted infections, an increase in surgical operations, and occurrences of bacterial sepsis are stimulating the growth of this segment. According to a report released in January 2021 by SAGE Journals, bacterial sepsis is the most prevalent form, with gram-negative bacteria infecting 62.2% of patients and gram-positive bacteria infecting 46.8%.

On the basis of testing type, in 2021, the laboratory testing type segment held the highest revenue share of over 85%. This is mostly because lab testing is more accurate than POC testing for the diagnosis of sepsis. Clinical laboratory testing allows a thorough examination of the pathogen, testing of lactate level and its medication resistance profile.

North America ruled the overall market by region, with a revenue share of nearly 39.7% in 2021. This expansion can be due to the region's increased use of advanced diagnostic tools because of the presence of strong healthcare infrastructure, the presence of prominent competitors, and a favourable reimbursement system. Additionally, it is anticipated that the increasing prevalence of infectious illnesses and sepsis will boost the need for cutting-edge diagnostic methods.

Key Players in Sepsis Diagnostics Market:

  • GE Healthcare
  • Cerner Corporation
  • Amara Health Analytics
  • Luminex Corporation
  • BioMerieux SA
  • Bruker Corporation
  • Epic Systems Corporations
  • Koninklijke Philips N.N.
  • McKesson Corporation
  • Wolters Kluwer NV
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific, Inc. 
  • Becton, Dickinson and Company

Before initiating a purchase, make a Pre-order enquiry and get a detailed overview of the content of the report.



Report AttributeDetails
Forecast Period2021 - 2030
Market size value in 2021USD 712.74 Million
Revenue forecast in 2030USD 1509.85 Million
Growth rateCAGR of 8.70%
The base year for estimation2021
Historical data2017 – 2021
UnitUSD Billion, CAGR (2021 - 2030)
SegmentationBy Technology, By Product, By Diagnostic Methods, By Pathogen, By Testing Types, By End-user and By Region.
By TechnologyMolecular Diagnostics, Immunoassay, Microbiology, and Other Technologies
By ProductInstruments, Assays and Reagents, Blood Culture Media and Other Products
By Diagnostic MethodsAutomated Diagnostics and Conventional Diagnostics
By PathogensFungal Sepsis, Bacterial Sepsis, and Other Pathogens
By Testing TypesLaboratory testing and POC testing
By End-UserHospital Laboratories, Reference Laboratories and Others
By RegionNorth America, Asia-Pacific, Europe, Middle-East and Africa, and South America
Country ScopeUS, Mexico, Germany, Mexico,  UK, France, Japan, China, India etc.
Company Usability ProfilesbioMérieux SA, Becton, Dickinson and Company,Thermo Fisher Scientific, Inc.,F. Hoffmann-La Roche AG, Luminex Corporation, Danaher Corporation (Beckman Coulter, Inc.),  Bruker Corporation, Wolters Kluwer NV,  Amara Health Analytics,  Cerner Corporation, Epic Systems Corporation, Mckesson Corporation, GE Healthcare, and Koninklijke Philips N.V.

 To read the summary of the report, visit the website at


Recent Developments

  • On 13th September 2022, in partnership with Clinical Excellence Commission (CEC), the Sydney Health Partners, University of Sydney, & NSW Health Pathology, eHealth NSW developed the AI-powered clinical decision support tool for determining the risk of sepsis.

  • On 23rd September 2022, The SeptiCyte RAPID test was created by the molecular diagnostic company Immunexpress in collaboration with Biocartis. It is an FDA-cleared, completely automated host-response assay that can distinguish sepsis from non-infection inflammation in suspected patients. 

  • In April 2022, Frequasense received £175,000 fund from LVYA Labs to develop technology that promptly identifies sepsis. Hospitals, GP offices, nursing homes, and paramedics will all use Frequasense's platform, which includes a fast finger prick test, once it is completely developed.

Related Reports

Diagnostic Electrocardiograph Market
The report on Diagnostic Electrocardiograph Market explains its restraining factors, challenges, opportunities, etc. The Diagnostic Electrocardiograph Market value was USD 5.39 Billion in 2021 and it will reach USD 5.58 Billion in 2030 with a 5.10% CAGR. Factors such as the high accuracy of ECG and increasing incidence of heart diseases are stimulating its growth rate. Key companies in this market are ACS Diagnostics, Midmark Corporation, Norav Medical, Nexus Lifecare, Innomed Medical, etc.

Point of Care Diagnostics Market
SMR's Point Of Care Diagnostics Market Report deciphers insights on its growth factors, restraints, opportunities, etc. The Point Of Care Diagnostics Market worth was USD 33.12 Billion in 2021, and by 2030 it will be worth USD 90.25 Billion at a CAGR of 11.78%. Increasing occurrences of infectious disease and a rising prevalence of POC testing procedures are the factors accelerating the growth of this market. Organizations operating in this market are Abbott Laboratories, Chembio Diagnostics, Trinity Biotech, Becton Dickinson and Company, etc.

Veterinary Infectious Disease Diagnostics Market
The Veterinary Infectious Disease Diagnostics Market Report by SMR explains its augmenting factors, challenges, restraints, etc. The Veterinary Infectious Disease Diagnostics Market value in 2021 was worth USD 1.76 billion, and by 2030 it will be worth USD 3.80 billion, at a 8.9%CAGR. Factors accelerating the market growth rate are the increasing incidence of zoonotic diseases and the growing healthcare expenditure, etc. Vital companies in this market are Heska Corporation, IDEXX Laboratories, Thermo Fisher Scientific, Neogen Corporation, etc.

Veterinary Reference Laboratory Market
The Veterinary Reference Laboratory Market Report by SMR outlines its opportunities, challenges, restraints, etc. The Veterinary Reference Laboratory Market value was worth USD 3.74 Billion in 2021, and by 2030 it will reach USD 9.74 Billion at a 11.2% CAGR. Factors stimulating the growth rate are rapid urbanization, increasing the population of companion animals, and increasing public awareness. Prominent players in this market include Animal and Plant Health Agency, Vetnostics, Heska Corporation, Thermo fisher scientific, Inc., Protatek International Inc., etc.

Digital Biomarkers Market
SMR's Digital Biomarkers Market Report provides an in-depth analysis of its opportunities, restraints, growth factors, etc. The Digital Biomarkers Market value in 2021 was USD 1.51 Billion, and by 2030 it will reach USD 23.56 Billion at a 35.27% CAGR. Increased healthcare expenditure, increased usage of smartwatches and smartphones, and government investments are stimulating the market's growth rate. Organizations playing a vital role in this market are Biogen, Inc, Eli Lily and Company, Novartis International AG, Pfizer Inc, Bayer AG, etc.

About Us:
Strategic Market Research facilitates the organizations globally in taking pivotal business decisions by furnishing the Syndicated and Customized Research Reports, which are highly precise in terms of market numbers. We believe that every firm, whether it is a startup which is in the Introduction stage of the Product Life cycle or an established one which is at the growth stage, requires market research services in order to streamline its key business blueprint. It may be related to Product Launch, Go to Market strategies, Competitive Analysis or new geographical penetration and expansion.

Contact Us:
Strategic Market Research LLP.
Sunil Kumar 
India: +91-8260836500
Email: info@strategicmarketresearch.com
Web: https://www.strategicmarketresearch.com
Blog: https://www.strategicmarketresearch.com/blog
Blog: https://www.strategicmarketresearch.com/blogs/property-management-industry-statistics
Press Release: https://www.strategicmarketresearch.com/press-releases
Connect Us:
LinkedIn: https://www.linkedin.com/company/strategic-market-research/
Twitter: https://twitter.com/smrstrategic
Facebook: https://www.facebook.com/StrategicMarketResearch
Instagram: https://www.instagram.com/strategicmarketresearchsmr/